Английская Википедия:ADB-FUBINACA

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013.[1][2] In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.[3]

The (S)-enantiomer of ADB-FUBINACA is described in a 2009 Pfizer patent[4] and has been reported to be a potent agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3.5 nM, respectively.[4][5] ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.

An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.

Side effects

One death through coronary arterial thrombosis has been linked to ADB-FUBINACA intoxication.[6]

Metabolism

Twenty-three ADB-FUBINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Major metabolic pathways were alkyl and indazole hydroxylation, terminal amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation.[7]

Legality

In the United States, ADB-FUBINACA is a Schedule I controlled substance.[8]

See also

Шаблон:Div col

Шаблон:Div col end

References

Шаблон:Reflist

Шаблон:Cannabinoids